Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced the close of a $103 million Series A financing co-led by MPM BioImpact and Novo Holdings, with participation from Arkin Bio Capital, Mitsui & Co. Global Investment, Plaisance Capital, FemHealth Ventures, and Palo Santo.
Leash Biosciences, an artificial intelligence and machine learning (AI/ML)-native biotechnology company unleashing machine learning to solve medicinal chemistry, today announced the completion of a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection.
Mitsui & Co., Ltd. (“Mitsui”, Head Office: Tokyo, President and CEO: Kenichi Hori), together with The Norinchukin Bank (President and CEO: Kazuto Oku), Mitsubishi Pencil Company, Limited (President: Shigehiko Suhara), and Nitto Denko Corporation (President: Hideo Takasaki) (hereinafter collectively “the Limited Partners”), announced its capital commitment to E12 Venture Capital Fund I, L.P. (“E12 Fund I”) upon its final closing.
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and Ensem Therapeutics, Inc. (ENSEM), a biotechnology company focusing on high-value and difficult-to-drug oncology targets, today announced an agreement for BeiGene to acquire an exclusive global license to an Investigational New Drug (IND) application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor.
BioNova today announced that Center of Drug Evaluation (CDE) had approved its investigational new drug (IND) application for BN104 for the treatment of relapsed/refractory (R/R) acute leukemia in China. Continue Reading
